Author: admin

Immune Thrombocytopenic Purpura as an Extraintestinal Manifestation in a Patient with Ulcerative Colitis 

Immune thrombocytopenic purpura (ITP) is characterized by the presence of autoantibodies against platelet membrane antigens, leading to immune-mediated platelet destruction. ITP is considered as a rare extraintestinal manifestation (EIM) of ulcerative colitis (UC).

Immune thrombocytopenic purpura (ITP) is characterized by the presence of autoantibodies against platelet membrane antigens, leading to immune-mediated platelet destruction. ITP is considered as a rare extraintestinal manifestation (EIM) of ulcerative colitis (UC).

Longitudinal multi-omics analyses link gut microbiome dysbiosis with recurrent urinary tract infections in women 

Recurrent urinary tract infections (rUTIs) are a major health burden worldwide, with history of infection being a significant risk factor. While the gut is a known reservoir for uropathogenic bacteria, the role of the microbiota in rUTI remains unclear.

Recurrent urinary tract infections (rUTIs) are a major health burden worldwide, with history of infection being a significant risk factor. While the gut is a known reservoir for uropathogenic bacteria, the role of the microbiota in rUTI remains unclear.

Dyslipidemia Management in Pregnancy: Why Is It Not Covered in the Guidelines? – Current Atherosclerosis Reports

Purpose of Review Despite the elevation of lipid values during pregnancy is mostly physiological, evidence suggest that it may be associated with adverse events. This article reviews the characteristics of lipid disorders and the possible management with dyslipidemia in pregnant women.

Purpose of Review Despite the elevation of lipid values during pregnancy is mostly physiological, evidence suggest that it may be associated with adverse events. This article reviews the characteristics of lipid disorders and the possible management with dyslipidemia in pregnant women.

Case Study: GLP-1 agonists in type 2 diabetes

Rybelsus (semaglutide) is a daily oral GLP-1 agonist for Type 2 diabetes that has A1C lowering as strong as injected Victoza (liraglutide) 1.8mg and somewhat better weight loss (-4.4kg versus -3.1kg to week 26), with similar gastrointestinal side effects. For proper oral absorption, it must be taken at least 30 minutes before the first food, beverage, or other oral medications of the day.

Rybelsus (semaglutide) is a daily oral GLP-1 agonist for Type 2 diabetes that has A1C lowering as strong as injected Victoza (liraglutide) 1.8mg and somewhat better weight loss (-4.4kg versus -3.1kg to week 26), with similar gastrointestinal side effects. For proper oral absorption, it must be taken at least 30 minutes before the first food, beverage, or other oral medications of the day.